The ratings reflect the company’s strong capitalization and conservative operating strategy. The ratings also consider the critical role and favorable profile the company has as part of the Pfizer group and its excellent operating performance in its first two years of operation.
Partially offsetting these positive rating factors are the company’s very large gross and net underwriting exposures to property losses and its dependence on reinsurance.
